Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
\* Eligibility Criteria： Inclusion Criiteria:~1. Male or female 18 to 75 years of age at the time of consent.~2. T2D patients with poorly controlled blood glucose treated with lifestyle intervention or stable dose of metformin (≥ 1000mg/day or maximum tolerated dose) within 2 months prior to screening.~3. HbA1c 7.5% ≤ 11.0% by local laboratory at screening.~4. Body mass index 20 ≤ BMI ≤ 35 kg/m2.~Exclusion Criteria:~1. Type 1 diabetes, special types of diabetes, or gestational diabetes.~2. Ketoacidosis or lactic acidosis within 6 months prior to screening.~3. History of severe hypoglycaemic episodes within 6 months prior to screening.~4. Acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, coronary intervention (except diagnostic angiography), transient ischemic attack (TIA), cerebrovascular accident, acute and chronic heart failure within 6 months before screening.~5. Clinically symptomatic liver disease, acute or chronic hepatitis, or transaminases (ALT and AST) and alkaline phosphatase (ALP) \> 2 times the upper limit of normal and total bilirubin above the upper limit of normal at screening.~6. The patient was previously diagnosed with autonomic neuropathy, manifested as urinary retention, resting tachycardia, orthostatic hypotension and diabetic diarrhea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI362 low dose cohort (Type: EXPERIMENTAL): Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.
- IBI362 medium dose cohort (Type: EXPERIMENTAL): Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
- IBI362 high dose cohort (Type: EXPERIMENTAL): Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).